Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
Phase 2
18–79
17 sites in AL, CA, MO +4
What this study is about
This Phase 2 study is focused on people with obesity. The primary outcome being measured is Incidence, severity and relationship of AEs/SAEs.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence, severity and relationship of AEs/SAEs
Secondary: Absolute change in body weight from Baseline, Change in HbA1c from Baseline, PK parameters including but not limited to AUC, PK parameters including but not limited to Cmax, PK parameters including but not limited to Ctrough, Percent change in body weight from Baseline, TPK parameters including but not limited to Tmax
Endocrinology